SEC Form 4 · accession 0000899243-17-003796
CytoDyn Inc. · CYDY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony Caracciolo
Officer — Executive Chairman · Director
Period of report
Feb 12, 2017
Accepted (ET)
Feb 13, 2017 · 4:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175680
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F1 | $0.76 | Feb 12, 2017 | A | 450,000 | A | — | Feb 12, 2027 | Common Stock | 450,000 | 450,000 | D |
| Stock Options (right to buy)F2 | $0.76 | Feb 12, 2017 | A | 550,000 | A | — | Feb 12, 2027 | Common Stock | 550,000 | 550,000 | D |
Explanation of responses
- F1Subject to stockholder approval of the increase in the number of shares authorized for issuance under the CytoDyn Inc. 2012 Equity Incentive Plan, as amended, at the next annual meeting, the options will vest upon the achievement of certain strategic milestones specified in the award agreement.
- F2The options will vest in equal monthly installments over the next two years, commencing on the first month following the grant date.